South Texas Money Management Ltd. lifted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 20.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 3,022 shares of the medical instruments supplier’s stock after buying an additional 507 shares during the period. South Texas Money Management Ltd.’s holdings in Becton Dickinson and were worth $647,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of BDX. Legacy Advisors LLC raised its holdings in Becton Dickinson and by 7,000.0% in the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after acquiring an additional 490 shares during the period. FTB Advisors Inc. raised its holdings in Becton Dickinson and by 114.2% in the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after acquiring an additional 290 shares during the period. Harfst & Associates Inc. raised its holdings in Becton Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after acquiring an additional 221 shares during the period. Exane Derivatives raised its holdings in Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock valued at $150,000 after acquiring an additional 628 shares during the period. Finally, Meeder Asset Management Inc. bought a new position in Becton Dickinson and in the 4th quarter valued at about $160,000. Institutional investors own 75.56% of the company’s stock.

Shares of Becton Dickinson and Co (NYSE:BDX) opened at $217.14 on Monday. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. The stock has a market cap of $57,811.89, a P/E ratio of 22.52, a P/E/G ratio of 1.49 and a beta of 1.12. Becton Dickinson and Co has a 52-week low of $175.66 and a 52-week high of $248.39.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same quarter last year, the business posted $2.33 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. analysts forecast that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Shareholders of record on Friday, March 9th will be given a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.38%. Becton Dickinson and’s dividend payout ratio is currently 229.01%.

Several research analysts have weighed in on BDX shares. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Friday, October 20th. Wells Fargo & Co reaffirmed a “positive” rating and set a $235.00 target price (up from $225.00) on shares of Becton Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank of Canada reaffirmed a “hold” rating and set a $210.00 target price on shares of Becton Dickinson and in a report on Wednesday, October 25th. Morgan Stanley raised their target price on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $245.00 target price on shares of Becton Dickinson and in a report on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and an average target price of $237.27.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://theolympiareport.com/2018/02/12/south-texas-money-management-ltd-acquires-507-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.